Frankfurt
21.11.24
08:02 Uhr
0,159 Euro
-0,004
-2,46 %
-2,46 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,176 | 0,176 | 16:35 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.11. | Mauna Kea Technologies Provides an Update on Its Recent Developments | 211 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 06.11. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 193 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website:... ► Artikel lesen | |
| 17.10. | Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance | 231 | Business Wire | Major New Study Presented at the World's Largest Gastroenterology Congress Validation of Mauna Kea's Growth Strategy with CellTolerance® in a $6 Billion a Year Market Opportunity
Regulatory... ► Artikel lesen | |
| 15.10. | Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales | 320 | Business Wire | Confirmation of lower breakeven point trajectory with 9% Reduction in Operational Expenses Q3 2024 Sales Growth of +24%1 Driven by New System Sales in the U.S. and Europe Official Launch of... ► Artikel lesen | |
| 04.10. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 326 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 01.10. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 210 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 16.09. | Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio | 213 | Business Wire | Recent clinical study published in Journal of Thoracic Disease supports the combination of Cellvizio with Electromagnetic Navigation Bronchoscopy to improve diagnosis and treatment of lung cancer... ► Artikel lesen | |
| 10.09. | Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio | 276 | Business Wire | Formal letter requests coverage of Cellvizio and its dedicated category I CPT Codes to significantly enhance early detection of Barrett's Esophagus and Esophageal Cancer Prevalence of Esophageal... ► Artikel lesen | |
| 09.08. | Mauna Kea Technologies: Monthly information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 412 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 25.07. | Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024 | 472 | Business Wire | Q2 2024 Sales Up 48% vs. Q1 but Down 20% Year-on-Year1 as U.S. Systems Sales Scheduled for the Second Half of 2024 and Temporary Reimbursement Reduction Impacting PPU Revenue U.S. PPU Volume... ► Artikel lesen | |
| 17.07. | Mauna Kea Technologies: Half-year Liquidity Contract Statement for H1 2024 With the Brokerage Firm Gilbert Dupont | 619 | Business Wire | Regulatory News:
Under the liquidity contract between the company MAUNA KEA TECHNOLOGIES (Paris:ALMKT) and the brokerage firm Gilbert Dupont, the following resources appeared on the liquidity account... ► Artikel lesen | |
| 04.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 348 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 26.06. | Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances | 357 | Business Wire | CellTolerance is a unique science-based program designed with physicians and dietitians New data presented at Digestive Disease Week 2024 reinforces the program's unique clinical value for patients... ► Artikel lesen | |
| 13.06. | Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024 | 399 | Business Wire | Pancreatic cancer remains difficult to diagnose accurately using conventional methods often leading to late-stage diagnoses or unnecessary surgeries New publications confirm once more Cellvizio's... ► Artikel lesen | |
| 07.06. | Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 6, 2024 | 290 | Business Wire | All the resolutions proposed by the Board of Directors were adopted
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and... ► Artikel lesen | |
| 06.06. | Mauna Kea Technologies Announces Joint Venture in China Obtained Class II Medical Device Business License | 340 | Business Wire | JV now operational to start selling products in China
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based... ► Artikel lesen | |
| 30.05. | Mauna Kea Technologies Winner of "Best New Technology Solution - Oncology" MedTech Breakthrough Award | 323 | Business Wire | Prestigious international program recognizes standout digital health medical technology products and companies 2024 awards program included more than 4,500 nominations from all around the world
Regulatory... ► Artikel lesen | |
| 21.05. | Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 6, 2024 and the Instructions for Participation | 316 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 17.05. | Mauna Kea Technologies: Monthly information regarding the total number of voting rights and shares comprising the share capital | 337 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 06.05. | Mauna Kea Technologies Announces 9 Presentations Demonstrating the Clinical Value of Cellvizio at Digestive Disease Week 2024 | 332 | Business Wire | AI, pancreatic cancer and food intolerance headline wide range of Cellvizio abstracts at gastroenterology's largest international meeting
Regulatory News:
Mauna Kea Technologies (Euronext... ► Artikel lesen |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA | 0,167 | +3,85 % | Sernova Aktie: Fortschritte bei Cell Pouch System | Die kanadische Biotechnologiefirma Sernova verzeichnet bedeutende Entwicklungen bei ihrer innovativen Cell Pouch Technologie. Das Unternehmen, das sich auf regenerative Medizinlösungen für chronische... ► Artikel lesen | |
| VITA 34 | 4,080 | -1,92 % | EQS-PVR: Vita 34 AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Vita 34 AG
Vita 34 AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.10.2024 / 15:01 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,720 | +1,49 % | Geratherm wird zum Löwenbändiger | Geratherm beteiligt sich mit 20 Prozent an BIOThermare. Die Gesellschaft ist durch die TV-Sendung "Höhle der Löwen" bekannt. Hergestellt werden Kalt/Warm-Kompressen mit patentierter Seegras-Gelfüllung.... ► Artikel lesen | |
| PLUS THERAPEUTICS | 1,154 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented positive... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,158 | +2,12 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium | SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas... ► Artikel lesen | |
| MEDICLIN | 2,600 | 0,00 % | EQS-AFR: MEDICLIN AG: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und Quartals-/Zwischenmitteilungen | EQS Vorabbekanntmachung Finanzberichte: MEDICLIN AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
MEDICLIN AG: Vorabbekanntmachung über die Veröffentlichung... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn-based Wound Care Hydrogel | BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| LIFEWARD | 1,850 | +0,54 % | Lifeward Ltd.: Coverage for ReWalk Personal Exoskeleton Expands as Hungary Joins the U.S. and Germany with a Policy Providing Access to Exoskeletons | ||
| VERU | 0,586 | -1,76 % | Veru Inc.: Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results | --Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected... ► Artikel lesen | |
| DIASORIN | 103,20 | -2,04 % | Milan: Strong day for DiaSorin | ||
| FRESENIUS | 32,740 | +1,65 % | Fresenius SE Aktie: Innovativer Schritt nach vorne | Die Fresenius SE Aktie verzeichnete am Handelstag einen leichten Rückgang, wobei der Kurs zwischenzeitlich um 2,0 Prozent auf 32,70 EUR fiel. Trotz dieser kurzfristigen Schwäche zeigen sich Analysten... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 92,70 | 0,00 % | Looking Into PROCEPT BioRobotics' Recent Short Interest | ||
| GERRESHEIMER | 69,95 | -0,29 % | Aixtron, Gerresheimer, Hugo Boss, K+S, Lufthansa, Rheinmetall u.a. - Aktien-Positionen der Shortseller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,004 (-2,46 %) liegt der Kurs bei 0,159 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.
